Compare Levi Strauss & Co. (LEVI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Levi Strauss & Co. vs TG Therapeutics Inc — how do they compare? Levi Strauss & Co. trades at $18.69 (market cap $7.31B), while TG Therapeutics Inc trades at $54.83 (market cap $8.16B). The key difference: Levi Strauss & Co. and TG Therapeutics Inc are close in size by market cap, and Levi Strauss & Co. pays a 3.36% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Levi Strauss & Co. for 70 Days and TG Therapeutics Inc for 16 Days on average.
| LEVI | TGTX | |
|---|---|---|
Market Cap | $7.31B | $8.16B |
Volume | 13,683,095 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.53 | $59.06 |
52-Week Low | $17.92 | $26.94 |
Typical Hold Time | 70 Days | 16 Days |
Enterprise Value | $8.86B | $8.37B |
Dividend Yield | 3.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Levi Strauss (LEVI) trades at $18.71, down 4.13% today, with a bearish technical outlook despite strong fundamentals. The company has beaten earnings estimates for four consecutive quarters, maintains a healthy gross margin of 62.81%, and shows improving cash flow trends. Analyst consensus remains strongly bullish with a $29.00 price target, representing 55% upside potential from current levels.
The stock presents a compelling value opportunity with a P/E of 12.5x and strong brand momentum, though technical weakness and recent cybersecurity incidents pose near-term risks. Wall Street's overwhelming buy rating (79%) suggests confidence in Levi's direct-to-consumer strategy and international expansion driving future growth.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
